Acquisitions - Narrative (Details)			3 Months Ended		12 Months Ended
	Oct. 10, 2021 USD ($) right $ / shares	Jun. 09, 2020 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Business Acquisition [Line Items]
Contingent consideration, liability				$ 80,477,000	$ 80,477,000
Cash consideration to Seller - net of cash acquired					950,000	$ 298,541,000	$ 0
Contingent consideration liability, high value		$ 230,000,000
Contingent consideration (gain) expense					(6,530,000)	1,900,000	$ 0
Adamas Pharmaceuticals
Business Acquisition [Line Items]
Acquisition-related costs						10,500,000
SPN-30 Regulatory and Commercial Activities
Business Acquisition [Line Items]
Contingent consideration liability, high value		130,000,000
SPN-830 FDA Acceptance Milestone
Business Acquisition [Line Items]
Contingent consideration liability, high value		25,000,000
SPN-830 NDA Approval Milestone
Business Acquisition [Line Items]
Contingent consideration liability, high value		105,000,000
SPN-830 First Commercial And Sale Milestone
Business Acquisition [Line Items]
Contingent consideration liability, high value		100,000,000
Future Sales Performance
Business Acquisition [Line Items]
Contingent consideration liability, high value		100,000,000
APOKYN
Business Acquisition [Line Items]
Contingent consideration liability, high value		35,000,000
APOKYN and SPN-830
Business Acquisition [Line Items]
Contingent consideration liability, high value		65,000,000
Adamas Pharmaceuticals
Business Acquisition [Line Items]
Cash consideration	$ 400,806,000
Contingents value rights | right	2
Rights per share (in dollars per share) | $ / shares	$ 0.50
Additional cash payments upon milestone achievements minimum	$ 150,000,000
Additional cash payments upon milestone achievements maximum	225,000,000
Additional cash payments upon milestone achievements minimum	0
Additional cash payments upon milestone achievements maximum	50,900,000
Contingent consideration, liability	10,300,000
Contingent consideration liability, high value	10,307,000
Intangible assets	$ 450,100,000
Acquisition-related costs						22,300,000
Severance related costs					15,600,000
Transaction costs				6,700,000	6,700,000
Net product sales					10,900,000
Operating earnings					(18,100,000)
Stock-based compensation expense						12,700,000
USWM Acquisition
Business Acquisition [Line Items]
Cash consideration		306,485,000
Additional cash payments upon milestone achievements minimum		0
Additional cash payments upon milestone achievements maximum		230,000,000
Contingent consideration, liability		74,800,000		70,170,000	70,170,000
Cash consideration to Seller - net of cash acquired		299,491,000
Contingent consideration liability, high value		74,800,000
Working capital adjustment				$ 2,300,000
Contingent consideration (gain) expense					40,900,000
Intangible assets		355,000,000
Acquisition-related costs						8,400,000
Net product sales					$ 132,134,000	$ 90,985,000
USWM Acquisition | Forecast
Business Acquisition [Line Items]
Working capital adjustment			$ 1,000,000
USWM Acquisition | Acquired In-process Research & Development
Business Acquisition [Line Items]
Intangible assets		124,000,000
USWM Acquisition | Acquired Developed Technology and Product Rights
Business Acquisition [Line Items]
Intangible assets		231,000,000
USWM Acquisition | Previously Reported
Business Acquisition [Line Items]
Cash consideration to Seller - net of cash acquired		297,200,000
Contingent consideration liability, high value		$ 115,700,000